|
| European Commission Issues Positive Decision for Approval of Seroquel XR as an Add-On Treatment of Major Depressive Disorder |
|
| AstraZeneca today announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy. |
|
 View full press release |
|
| This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. |
|
No comments:
Post a Comment